Oncolytic viruses: Smart therapeutics for smart cancers

Future Oncology

Volumn 8, Issue 1, 2012, Pages 1-4

  Auer, Rebecca ^a   Bell, John C ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

antitumor immunity; cancer therapeutic; oncolytic virus; vascular targeting

Indexed keywords

IMATINIB; ONCOLYTIC VIRUS; TUMOR ANTIGEN; VASCULOTROPIN RECEPTOR;

APOPTOSIS; BLOOD FLOW; CANCER PATIENT; GENE MUTATION; GENETIC ENGINEERING; GENOME; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LIVER; MEDICAL EDUCATION; NEOPLASM; PARASITE; PRIORITY JOURNAL; PROTEIN PROCESSING; REOVIRUS; REVIEW; SIGNAL TRANSDUCTION; SPLEEN; TUMOR CELL; TUMOR VASCULARIZATION; VACCINIA VIRUS; VASCULAR ENDOTHELIUM; VIRUS REPLICATION;

ANIMALS; HUMANS; IMMUNE EVASION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TUMOR ESCAPE;

EID: 83755173514     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.134     Document Type: Review

References (22)

1. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 9, 64-71 (2009).
2. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 5, 965-976 (2005). (Pubitemid 41766784)
3. Lee W, Jiang Z, Liu J et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465, 473-477 (2010).
4. Thirukkumaran C, Morris DG. Oncolytic viral therapy using reovirus. Methods Mol. Biol. 542, 607-634 (2009).
5. Goel S, Duda DG, Xu L et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91, 1071-1121 (2011).
6. Allen C, Vongpunsawad S, Nakamura T et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res. 66, 11840-11850 (2006). (Pubitemid 46094196)
7. Russell SJ, Peng KW. Measles virus for cancer therapy. Curr. Top. Microbiol. Immunol. 330, 213-241 (2009).
8. Kim M, Williamson CT, Prudhomme J et al. The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene 29, 3990-3996 (2010).
9. Breitbach CJ, Burke J, Jonker D et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99-102 (2011).
10. Yun CO. Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr. Opin. Mol. Ther. 10, 356-361 (2008).
11. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J. Natl Cancer Inst. 98, 1482-1493 (2006). (Pubitemid 44605593)
12. Ilett EJ, Prestwich RJ, Kottke T et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther. 16, 689-699 (2009).
13. Ilett EJ, Bárcena M, Errington-Mais F et al. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin. Cancer Res. 17, 2767-2776 (2011).
14. Kirn DH, Wang Y, Liang W, Contag CH, Thorne SH. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res. 68, 2071-2075 (2008). (Pubitemid 351521777)
15. Jing Y, Tong C, Zhang J et al. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res. 69, 1459-1468 (2009).
16. Breitbach CJ, De Silva NS, Falls TJ et al. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19, 886-894 (2011).
17. Ong HT, Trej,TR, Pham, LD, Oberg AL, Russell SJ, Peng KW. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol. Ther. 17(6), 1012-1021 (2009).
18. Breitbach CJ, Paterson JM, Lemay CG et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15, 1686-1693 (2007). (Pubitemid 47289013)
19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
20. Wongthida P, Diaz RM, Galivo F et al. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol. Ther. 19, 150-158 (2011).
21. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6, 409-422 (1999). (Pubitemid 129667814)
22. Sivendran S, Pan M, Kaufman HL, Saenger Y. Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert Opin. Biol. Ther. 10, 1145-1153 (2010).